POORLY DIFFERENTIATED THYROID GLAND CARCINOMA
Clinical trials for POORLY DIFFERENTIATED THYROID GLAND CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new POORLY DIFFERENTIATED THYROID GLAND CARCINOMA trials appear
Sign up with your email to follow new studies for POORLY DIFFERENTIATED THYROID GLAND CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug cocktail shows promise for Hard-to-Treat thyroid cancer
Disease control OngoingThis phase II trial tests a combination of three drugs—cabozantinib, nivolumab, and ipilimumab—in 11 patients with advanced thyroid cancer that no longer responds to radioactive iodine or prior targeted therapy. The goal is to see if this mix can shrink tumors or stop them from g…
Matched conditions: POORLY DIFFERENTIATED THYROID GLAND CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Could your own tumor cells fight cancer? new trial tests immune cell therapy
Disease control OngoingThis phase 2 trial tests a treatment called LN-145, made from a patient's own immune cells taken from their tumor. These cells are grown in a lab and then given back to the patient to attack the cancer. The study includes people with ovarian cancer, triple-negative breast cancer,…
Matched conditions: POORLY DIFFERENTIATED THYROID GLAND CARCINOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
Targeted drug before surgery shows promise for RET-Altered thyroid cancer
Disease control OngoingThis phase 2 trial tests whether giving selpercatinib before standard surgery can shrink tumors in people with RET-altered thyroid cancer. About 30 participants with advanced or recurrent disease will receive the drug and then undergo surgery. The goal is to see if the drug impro…
Matched conditions: POORLY DIFFERENTIATED THYROID GLAND CARCINOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
Can a cancer drug make radioactive iodine work again for thyroid tumors?
Disease control OngoingThis phase 2 trial tests whether the targeted drug trametinib can help radioactive iodine (I-131) work better in people with advanced thyroid cancer that has returned or spread. The study includes 34 participants whose cancer no longer responds to standard radioactive iodine trea…
Matched conditions: POORLY DIFFERENTIATED THYROID GLAND CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
New hope for rare, aggressive thyroid cancer: drug combo shows promise
Disease control OngoingThis phase 2 trial tests whether combining lenvatinib (a targeted drug that blocks cancer growth) with pembrolizumab (an immunotherapy that helps the immune system attack cancer) can improve outcomes for people with advanced anaplastic thyroid cancer that cannot be surgically rem…
Matched conditions: POORLY DIFFERENTIATED THYROID GLAND CARCINOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
Immunotherapy cocktail takes on deadly thyroid cancer
Disease control OngoingThis phase 2 trial tests whether adding the immunotherapy drug atezolizumab to standard chemotherapy can help people with anaplastic or poorly differentiated thyroid cancer live longer. About 50 patients with advanced or inoperable cancer are receiving different drug combinations…
Matched conditions: POORLY DIFFERENTIATED THYROID GLAND CARCINOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
New combo therapy shows promise for Radioiodine-Resistant thyroid cancer
Disease control OngoingThis phase 2 trial tests a combination of the immunotherapy drug PDR001 with either trametinib or dabrafenib in 19 patients with thyroid cancer that no longer responds to radioiodine treatment. The goal is to see if the combination can shrink tumors. The study is active but no lo…
Matched conditions: POORLY DIFFERENTIATED THYROID GLAND CARCINOMA
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC